|Inside This Issue: Neurotech 2011
Top News Alerts: Product Updates, Deals & Financings
Conference Highlights: Neurotech Investing and Partnering 2011
Page 2: Orphan Disorders - Risky or Right?
Page 13: Growth Factors Make a Comeback with Next Gen BBB Technology
Company Spotlight: Nexstim
Subscribe now to access over 50 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Neurotech Revenues Reach $150 Billion
NeuroInsights released the latest industry numbers and trends in The Neurotech Industry 2011 Report published on May 25. Global neurotech industry revenues grew 4.8% to $149.8 billion. The largest sector, neuropharmaceuticals recorded revenues of $126.6 billion with 4.7% annual growth compared to 4.1% growth for the overall global pharmaceutical industry. The fastest growth areas within neuropharmaceuticals include retinal disorders, addiction, and antipsychotics. Neurodevices pulled in revenues of $7.98 billion with 13% annual growth. Highest growth areas include peripheral nerve stimulation, as well as neurovascular devices. Neurodiagnostics recorded revenues of $15.3 billion and 2% annual growth. This represents a significant rebound compared to 2009, when reimbursement cutbacks caused a huge decease in capital equipment purchases. M&A picked up in 2011 compared to 2010...
Investors and Executives Gather at Neurotech Investing and Partnering 2011
While the message to entrepreneurs at the investment panel of last year's Neurotech Investing and Partnering Conference was unequivocal and clear, "donít come knocking unless you have a late stage compound with a well-characterized mechanism of action," this year's panel displayed much less like-mindedness and a more varied interest. Whether that is a sign we are returning to a more normal investment climate, it may be too early to tell. But it is obvious that investors are no longer all fixated on the Phase II asset in the hopes of a quick exit...
Nexstim: Mapping a Path to Success
Finnish company Nexstim was founded in 2000 by Professor Risto Ilmoniemi based on intellectual property generated during eight years of research at the BioMag laboratory of Helsinki University General Hospital. The technology allows for stereotactically guided transcranial magnetic stimulation (TMS) which can be valuable for presurgical mapping as well as precision therapeutic TMS. Nexstim has raised over Ä30 million so far, Ä13 million of which closed just a few weeks ago. NeuroInsights spoke with the Nexstim executive team...Companies Covered In This Issue Include: Alkermes, BioLineRx, Naurex, Sova, Prexa, Astellas, BioFocus, Gelesis, Neuronetics, Second Sight, Rules-based Medicine, Sanofi-Aventis, Proteostasis, Elan, AgenBio, Checkpoint Surgical, Vistagen, Evotec, Psychogenics, NeuroHealing, Xenon, BrainScope, Shionogi, Codman, Afraxis, Neuraltus, Synapse Biomedical, Ariel Pharmaceuticals, Shire, Bioness, Alimera, ImThera, Otsuka, CNS Response, aLIMERA, CNS Response, ImThera, Otsuka, Bioness, EnVivo, EnteroMedics, Shire, Medtronic, Acorda, Biogen Idec, Regeneron, Insys, NeuroSigma, Teva, Cephalon, Prexa, Geron, Intrapace, Horizon, Dormir, Angion, Haptares, Lectec, Axogen, NMT Medical, Horizon, Lundbeck, Johnson & Johnson, Novartis and more